Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts

Journal of Cellular Biochemistry

Volumn 106, Issue 4, 2009, Pages 563-569

  Mizutani, Kosuke ^a   Sud, Sudha ^a   Pienta, Kenneth J ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c NONE   (United States)

Author keywords

CCL2; CD11b; IL 6; IL 8; Osteoclast; Prostate cancer; RANKL

Indexed keywords

CD11B ANTIGEN; COLONY STIMULATING FACTOR 1; CYTOKINE; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT;

ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ANTIGENS, CD11B; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; CYTOKINES; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MALE; OSTEOCLASTS; PARACRINE COMMUNICATION; PROSTATIC NEOPLASMS; RANK LIGAND;

EID: 62649173106     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22021     Document Type: Article

References (23)

1. Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ. 2005. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65:11001-11009.
2. Boyce BF, Xing L. 2008. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473:139-146.
3. Del Fattore A, Teti A, Rucci N. 2008. Osteoclast receptors and signaling. Arch Biochem Biophys 473:147-160.
4. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA. 1996. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137:4058-4060.
5. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. 2001. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 97:3349-3353.
6. Hayashi H, Nakahama K, Sato T, Tuchiya T, Asakawa Y, Maemura T, Tanaka M, Morita M, Morita I. 2008. The role of Mac-1 (CD11b/CD18) in osteoclast differentiation induced by receptor activator of nuclear factor-kappa B ligand. FEBS Lett 582:3243-3248.
7. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. 1999. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25:255-259.
8. Isaacs JT. 2005. New strategies for the medical treatment of prostate cancer. BJU Int 96: Suppl 2 35-40.
9. Keller ET, Dai J, Escara-Wilke J, Hall CL, Ignatoski K, Taichman RS, Keller J. 2007. New trends in the treatment of bone metastasis. J Cell Biochem 102:1095-1102.
10. Kim MS, Day CJ, Morrison NA. 2005. MCP-1 is induced by receptor activator of nuclear factor-[kappa]B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem 280:16163-16169.
11. Kim MS, Day CJ, Selinger CI, Magno CL, Stephens SR, Morrison NA. 2006. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption. J Biol Chem 281:1274-1285.
12. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. 2007. Molecular biology of bone metastasis. Mol Cancer Ther 6:2609-2617.
13. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. 2003. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32:1-7.
14. Li P, Schwarz EM, O'Keefe RJ, Ma L, Looney RJ, Ritchlin CT, Boyce BF, Xing L. 2004. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum 50:265-276.
15. Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC. 2007. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J Biol Chem 282:33098-33106.
16. Liao J, Li X, Koh AJ, Berry JE, Thudi N, Rosol TJ, Pienta KJ, McCauley LK. 2008. Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. Int J Cancer 123:2267-2278.
17. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. 2005. Pathogenesis and treatment of prostate cancer bone metastases: Targeting the lethal phenotype. J Clin Oncol 23:8232-8241.
18. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J. 2007. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 67:3646-3653.
19. Murdoch C, Muthana M, Coffelt SB, Lewis CE. 2008. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8:618-631.
20. Quinn JM, Neale S, Fujikawa Y, McGee JO, Athanasou NA. 1998. Human osteoclast formation from blood monocytes, peritoneal macrophages, and bone marrow cells. Calcif Tissue Int 62:527-531.
21. Taichman RS, Loberg RD, Mehra R, Pienta KJ. 2007. The evolving biology and treatment of prostate cancer. J Clin Invest 117:2351-2361.
22. Takayanagi H. 2005. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83:170-179.
23. Walczak JR, Carducci MA. 2007. Prostate cancer: A practical approach to current management of recurrent disease. Mayo Clin Proc 82:243-249.